Abstract
A trial of melphalan and methyl-gag was undertaken in 16 patients with metastatic renal cell carcinoma. Among 14 evaluable patients, 6 had stabilization of disease. No significant responses were observed. While both drugs have produced occasional responses in renal cancer, their combination shows no therapeutic advantage.
MeSH terms
-
Adult
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Carcinoma, Renal Cell / drug therapy*
-
Carcinoma, Renal Cell / secondary
-
Female
-
Humans
-
Kidney Neoplasms / drug therapy*
-
Kidney Neoplasms / secondary
-
Male
-
Melphalan / administration & dosage
-
Middle Aged
-
Mitoguazone / administration & dosage